307 related articles for article (PubMed ID: 19506801)
1. Autotaxin.
Boutin JA; Ferry G
Cell Mol Life Sci; 2009 Sep; 66(18):3009-21. PubMed ID: 19506801
[TBL] [Abstract][Full Text] [Related]
2. Lysophosphatidic acids, cyclic phosphatidic acids and autotaxin as promising targets in therapies of cancer and other diseases.
Gendaszewska-Darmach E
Acta Biochim Pol; 2008; 55(2):227-40. PubMed ID: 18560605
[TBL] [Abstract][Full Text] [Related]
3. [Secretion and role of autotaxin and lysophosphatidic acid in adipose tissue].
Saulnier-Blache JS
J Soc Biol; 2006; 200(1):77-81. PubMed ID: 17144165
[TBL] [Abstract][Full Text] [Related]
4. Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs.
Kanda H; Newton R; Klein R; Morita Y; Gunn MD; Rosen SD
Nat Immunol; 2008 Apr; 9(4):415-23. PubMed ID: 18327261
[TBL] [Abstract][Full Text] [Related]
5. Lipid generation and signaling in ovarian cancer.
Xu Y; Wang D; Wang Z
Cancer Treat Res; 2009; 149():241-67. PubMed ID: 19763440
[No Abstract] [Full Text] [Related]
6. Autotaxin and lysophosphatidic acid stimulate intestinal cell motility by redistribution of the actin modifying protein villin to the developing lamellipodia.
Khurana S; Tomar A; George SP; Wang Y; Siddiqui MR; Guo H; Tigyi G; Mathew S
Exp Cell Res; 2008 Feb; 314(3):530-42. PubMed ID: 18054784
[TBL] [Abstract][Full Text] [Related]
7. High-fat diet, obesity and prostate disease: the ATX-LPA axis?
Kulkarni P; Getzenberg RH
Nat Clin Pract Urol; 2009 Mar; 6(3):128-31. PubMed ID: 19204739
[No Abstract] [Full Text] [Related]
8. Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells.
Vidot S; Witham J; Agarwal R; Greenhough S; Bamrah HS; Tigyi GJ; Kaye SB; Richardson A
Cell Signal; 2010 Jun; 22(6):926-35. PubMed ID: 20100569
[TBL] [Abstract][Full Text] [Related]
9. Role of lysophosphatidic acid in the regulation of uterine leiomyoma cell proliferation by phospholipase D and autotaxin.
Billon-Denis E; Tanfin Z; Robin P
J Lipid Res; 2008 Feb; 49(2):295-307. PubMed ID: 18024704
[TBL] [Abstract][Full Text] [Related]
10. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid.
Kishi Y; Okudaira S; Tanaka M; Hama K; Shida D; Kitayama J; Yamori T; Aoki J; Fujimaki T; Arai H
J Biol Chem; 2006 Jun; 281(25):17492-17500. PubMed ID: 16627485
[TBL] [Abstract][Full Text] [Related]
11. Evidence for de novo synthesis of lysophosphatidic acid in the spinal cord through phospholipase A2 and autotaxin in nerve injury-induced neuropathic pain.
Ma L; Uchida H; Nagai J; Inoue M; Aoki J; Ueda H
J Pharmacol Exp Ther; 2010 May; 333(2):540-6. PubMed ID: 20123931
[TBL] [Abstract][Full Text] [Related]
12. A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation.
Gierse J; Thorarensen A; Beltey K; Bradshaw-Pierce E; Cortes-Burgos L; Hall T; Johnston A; Murphy M; Nemirovskiy O; Ogawa S; Pegg L; Pelc M; Prinsen M; Schnute M; Wendling J; Wene S; Weinberg R; Wittwer A; Zweifel B; Masferrer J
J Pharmacol Exp Ther; 2010 Jul; 334(1):310-7. PubMed ID: 20392816
[TBL] [Abstract][Full Text] [Related]
13. Lysophosphatidic acid and invasion.
Wang F; Fishman DA
Cancer Treat Res; 2009; 149():269-96. PubMed ID: 19763441
[No Abstract] [Full Text] [Related]
14. Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts.
David M; Wannecq E; Descotes F; Jansen S; Deux B; Ribeiro J; Serre CM; Grès S; Bendriss-Vermare N; Bollen M; Saez S; Aoki J; Saulnier-Blache JS; Clézardin P; Peyruchaud O
PLoS One; 2010 Mar; 5(3):e9741. PubMed ID: 20305819
[TBL] [Abstract][Full Text] [Related]
15. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid.
Tanaka M; Okudaira S; Kishi Y; Ohkawa R; Iseki S; Ota M; Noji S; Yatomi Y; Aoki J; Arai H
J Biol Chem; 2006 Sep; 281(35):25822-30. PubMed ID: 16829511
[TBL] [Abstract][Full Text] [Related]
16. [Clinical introduction of lysophosphatidic acid and autotaxin assays].
Yatomi Y
Rinsho Byori; 2010 Jun; 58(6):631-5. PubMed ID: 20662276
[TBL] [Abstract][Full Text] [Related]
17. Submucosal connective tissue-type mast cells contribute to the production of lysophosphatidic acid (LPA) in the gastrointestinal tract through the secretion of autotaxin (ATX)/lysophospholipase D (lysoPLD).
Mori K; Kitayama J; Aoki J; Kishi Y; Shida D; Yamashita H; Arai H; Nagawa H
Virchows Arch; 2007 Jul; 451(1):47-56. PubMed ID: 17554559
[TBL] [Abstract][Full Text] [Related]
18. S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool.
Ferry G; Moulharat N; Pradère JP; Desos P; Try A; Genton A; Giganti A; Beucher-Gaudin M; Lonchampt M; Bertrand M; Saulnier-Blache JS; Tucker GC; Cordi A; Boutin JA
J Pharmacol Exp Ther; 2008 Dec; 327(3):809-19. PubMed ID: 18755937
[TBL] [Abstract][Full Text] [Related]
19. Autotaxin stimulates urokinase-type plasminogen activator expression through phosphoinositide 3-kinase-Akt-nuclear [corrected] factor kappa B signaling cascade in human melanoma cells.
Lee J; Duk Jung I; Gyo Park C; Han JW; Young Lee H
Melanoma Res; 2006 Oct; 16(5):445-52. PubMed ID: 17013094
[TBL] [Abstract][Full Text] [Related]
20. Lysophospholipids in the limelight: autotaxin takes center stage.
Moolenaar WH
J Cell Biol; 2002 Jul; 158(2):197-9. PubMed ID: 12135981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
